News from celsion corporation

Jun 20, 2014, 09:00 ET

Celsion Corporation Completes Acquisition of EGEN, Inc.

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of...

Jun 10, 2014, 10:00 ET

Celsion Closes Second $5 Million Tranche under Loan Facility Agreement with Hercules Technology Growth Capital

 Celsion Corporation (NASDAQ: CLSN) today announced that it has closed the second $5 million tranche under its $20 million Loan and Security...

Jun 10, 2014, 07:30 ET

Celsion Corporation to Acquire EGEN, Inc.

 Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical...

May 21, 2014, 08:00 ET

Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

 Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical...

May 16, 2014, 08:00 ET

Celsion Corporation Announces ThermoDox® Abstract Accepted at the 2014 American Society of Clinical Oncology 50th Annual Meeting

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that an abstract on its Phase III HEAT Study of...

May 08, 2014, 08:00 ET

Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March...

May 01, 2014, 08:00 ET

Celsion Corporation to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014

 Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss first quarter 2014 financial...

Apr 24, 2014, 06:00 ET

Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014

 Celsion Corporation (NASDAQ: CLSN) today announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review...

Apr 10, 2014, 08:00 ET

Celsion Announces ThermoDox® HCC Program to be discussed at the 2014 European Conference on Interventional Oncology in Berlin, Germany

Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, Professor and Director of the Diagnostic...

Apr 09, 2014, 08:00 ET

Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound

Celsion Corporation (NASDAQ: CLSN) announced today that data supporting the development of ThermoDox®, its proprietary heat-activated...

Mar 13, 2014, 08:00 ET

Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31,...

Mar 06, 2014, 08:00 ET

Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014

 Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2013 financial results...

Feb 27, 2014, 16:05 ET

Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer

 Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox®...

Feb 24, 2014, 08:00 ET

Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer

Celsion Corporation (NASDAQ: CLSN) announced today that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the...

Jan 27, 2014, 08:00 ET

Celsion Corporation Announces Updated Overall Survival Results from Phase III HEAT Study of ThermoDox® in Primary Liver Cancer

 Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the...

Jan 21, 2014, 08:00 ET

Celsion Corporation Initiates Development Program for Glioblastoma Brain Tumors with ThermoDox® and HIFU

Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the company is formalizing a program to...

Jan 15, 2014, 09:07 ET

Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering

 Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has received commitments from institutional investors to...

Dec 13, 2013, 08:00 ET

Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the presentation of the combined clinical study results...

Nov 26, 2013, 08:00 ET

Celsion Corporation Announces Strategic Loan Facility

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, announced today that it has entered into a loan agreement with Hercules...

Nov 12, 2013, 08:00 ET

Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer